70601-63-7

Basic information

• Product Name: O-Methyl-D-tyrosine hydrochloride
• Synonyms: O-Methyl-D-tyrosine hydrochloride;(R)-4-Methoxyphenylalanine Hydrochloride Salt;(R)-2-Amino-3-(4-methoxyphenyl)propanoic acid hydrochloride;4-Methoxy-D-Phenylalanine hydrochloride
• CAS NO: 70601-63-7
• Molecular Formula: C₁₀H₁₃NO₃*ClH
• Molecular Weight: 231.678
• Mol File: 70601-63-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: O-Methyl-D-tyrosine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: O-Methyl-D-tyrosine hydrochloride(70601-63-7)
• EPA Substance Registry System: O-Methyl-D-tyrosine hydrochloride(70601-63-7)

Safety Data

• Hazardous Substances Data: 70601-63-7(Hazardous Substances Data)

Usage

General Description

O-Methyl-D-tyrosine hydrochloride, also known as metirosine, is a chemical compound that is derived from the amino acid tyrosine. It is a tyrosine hydroxylase inhibitor and is commonly used in the treatment of certain types of cancer, particularly pheochromocytoma and neuroblastoma. O-Methyl-D-tyrosine hydrochloride works by inhibiting the activity of the enzyme tyrosine hydroxylase, which is involved in the production of catecholamines such as dopamine, norepinephrine, and epinephrine. By reducing the production of these neurotransmitters, O-Methyl-D-tyrosine hydrochloride can help to control the symptoms of these types of cancer. Additionally, it has also been investigated for its potential use in the treatment of other conditions such as Parkinson's disease and cocaine addiction.

Upstream product

• 53612-87-6 2-acetylamino-2-(4-methoxybenzyl)malonic acid diethyl ester 
• 81961-88-8 ethyl 2-acetylamino-2-cyano-3-(4-methoxyphenyl)propanoate 
• 824-94-2 p-methoxybenzyl chloride 
• 7479-01-8 O-methyl-tyrosine methyl ester; hydrochloride 
• 70601-62-6 (D)-N-acetyl-4-methoxy-phenylalanine 

Downstream Products

• 17355-19-0 methyl (R)-2-amino-3-(4-methoxyphenyl)propanoate 
• 856571-11-4 2-(2-aminobenzoylamino)-3-(4-methoxyphenyl)propionic acid ethyl ester 
• 856571-30-7 2-{2-[(1H-indole-2-carbonyl)amino]benzoylamino}-3-(4-methoxyphenyl)propionic acid ethyl ester 
• 52177-40-9 (L)-4-Methoxy-phenylalanine benzyl ester hydrochloride 
• 70529-50-9 methyl 2-acetylamino-3-(4-methoxyphenyl)propanoate 
• 1575605-55-8 allyl 2-acetylamino-3-(4-methoxyphenyl)propanoate 
• 1575603-62-1 butyl 2-acetylamino-3-(4-methoxyphenyl)propanoate 
• 17355-24-7 (S)-N-acetyl-3-(4-methoxyphenyl)alanine methyl ester 
• 17355-24-7 methyl (R)-2-acetamido-3-(4-methoxyphenyl)propanoate 
• 1575603-64-3 allyl 2-acetylamino-3-(4-methoxyphenyl)propanoate 
• 7479-01-8 O-methyl-tyrosine methyl ester; hydrochloride 
• 1575604-59-9 C₁₄H₂₁NO₃*ClH 
• 82611-59-4 2-(((benzyloxy)carbonyl)amino)-3-(4-methoxyphenyl)propanoic acid 

Relevant articles and documents

BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS

The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"

In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.

Octapeptides and methods for their production

New octapeptides having the formula Prot Grp-R-Trp-Ser-Tyr-R2 -Leu-Arg-Pro-R3 ; salts thereof; wherein R is Gln, Gln (bzl), His (bzl), Ser (bzl), Pro, Leu, Tyr (bzl), Ile, Cys (bzl) or Phe, R2 is D-Phe, D-Ala, D-Leu, D-Trp, D-Tyr, D-Tyr (Me), D-Ser, D-Met, D-Arg, D-Val, D-His, D-Gln, D-Phs, D-Thr, D-Pro, D-Me5 Phe or D-Asn and R3 is NH2, NH(lower alkyl), N-(lower alkyl)2, NH-benzyl, NHCH2 CH2 N-(lower alkyl)2 or NH-CH2 CH2 SO2 NH-benzyl; methods for their production; certain peptide intermediates and their salts used in the production thereof; and the use of said octapeptides as luteinizing hormone releasing factor antagonists.